Jennifer Delmerico
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jennifer Delmerico has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Christine B. Ambrosone
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, USA
38 shared publications - Song Yao
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, USA
38 shared publications - Haiyang Sheng
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York
37 shared publications - Lawrence H. Kushi
Division of Research, Kaiser Permanente Northern California, Oakland, USA
37 shared publications - Marilyn L. Kwan
Division of Research Kaiser Permanente Northern California Pleasanton California USA
37 shared publications - Qianqian Zhu
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, USA
37 shared publications
Latest Publications
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (3) , 408-417
Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors
PURPOSE: Minoritized racial/ethnic groups are historically under-represented in cancer clinical trials, which may be exacerbated in recent trials on immune checkpoint inhibitors (ICIs). We examined the representation and reporting of the racial/ethnic composition of participants in clinical trials on ICIs. METHODS: We examined English full-text trials on ICIs published from 2007 to 2022. Information on trial characteristics and racial/ethnic composition of participants was extracted from published papers or ClinicalTrials.gov. Differences in participation by publication year, ICI agent, and cancer site were analyzed. Enrollment-incidence ratio (EIR) was calculated to compare the proportion of minoritized racial/ethnic group patients in US-based trials against age-adjusted cancer incidence data available for the US population. An EIR > 1 signified over-representation, whereas an EIR P values ≤.05). CONCLUSION: Disparities in the representation and reporting of minoritized racial/ethnic groups persist in recent trials on ICIs, necessitating collaborative efforts for improved diversity and equitable cancer treatment access.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (3) , 408-417
Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors
PURPOSE: Minoritized racial/ethnic groups are historically under-represented in cancer clinical trials, which may be exacerbated in recent trials on immune checkpoint inhibitors (ICIs). We examined the representation and reporting of the racial/ethnic composition of participants in clinical trials on ICIs. METHODS: We examined English full-text trials on ICIs published from 2007 to 2022. Information on trial characteristics and racial/ethnic composition of participants was extracted from published papers or ClinicalTrials.gov. Differences in participation by publication year, ICI agent, and cancer site were analyzed. Enrollment-incidence ratio (EIR) was calculated to compare the proportion of minoritized racial/ethnic group patients in US-based trials against age-adjusted cancer incidence data available for the US population. An EIR > 1 signified over-representation, whereas an EIR P values ≤.05). CONCLUSION: Disparities in the representation and reporting of minoritized racial/ethnic groups persist in recent trials on ICIs, necessitating collaborative efforts for improved diversity and equitable cancer treatment access.
- Open Access
- 20 January 2024
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-7
A polygenic score associated with fracture risk in breast cancer patients treated with aromatase inhibitors
Identifying women at high risk of osteoporotic fracture from aromatase inhibitor (AI) therapy for breast cancer is largely based on known risk factors for healthy postmenopausal women, which might not accurately reflect the risk in breast cancer patients post-AI therapy. To determine whether a polygenic score associated with fracture in healthy women is also significant in women treated with AIs for breast cancer, we used data from a prospective observational cohort of 2152 women diagnosed with hormonal receptor positive breast cancer treated with AIs as the initial endocrine therapy and examined a polygenic score of heel quantitative ultrasound speed of sound (gSOS) in relation to incident osteoporotic fracture after AI therapy during a median 6.1 years of follow up after AI initiation. In multivariable models, patients with the second and third highest tertiles (T) versus the lowest tertile of gSOS had significantly lower risk of fracture (T2: adjusted HR = 0.61, 95% CI: 0.46-0.80; T3: adjusted HR = 0.53, 95% CI: 0.40-0.70). The lower risk of fracture in patients with the highest tertile of gSOS remained significant after further adjustment for BMD at the hip (T3: adjusted HR = 0.62, 95% CI: 0.42-0.91). In conclusion, our analysis showed gSOS as a novel genetic predictor for fracture risk independent of BMD among breast cancer patients treated with AIs. Future studies are warranted to evaluate the performance of incorporating gSOS in prediction models for the risk of AI-related fracture in breast cancer patients.
- 20 January 2024
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-7
Open AccessA polygenic score associated with fracture risk in breast cancer patients treated with aromatase inhibitors
Identifying women at high risk of osteoporotic fracture from aromatase inhibitor (AI) therapy for breast cancer is largely based on known risk factors for healthy postmenopausal women, which might not accurately reflect the risk in breast cancer patients post-AI therapy. To determine whether a polygenic score associated with fracture in healthy women is also significant in women treated with AIs for breast cancer, we used data from a prospective observational cohort of 2152 women diagnosed with hormonal receptor positive breast cancer treated with AIs as the initial endocrine therapy and examined a polygenic score of heel quantitative ultrasound speed of sound (gSOS) in relation to incident osteoporotic fracture after AI therapy during a median 6.1 years of follow up after AI initiation. In multivariable models, patients with the second and third highest tertiles (T) versus the lowest tertile of gSOS had significantly lower risk of fracture (T2: adjusted HR = 0.61, 95% CI: 0.46-0.80; T3: adjusted HR = 0.53, 95% CI: 0.40-0.70). The lower risk of fracture in patients with the highest tertile of gSOS remained significant after further adjustment for BMD at the hip (T3: adjusted HR = 0.62, 95% CI: 0.42-0.91). In conclusion, our analysis showed gSOS as a novel genetic predictor for fracture risk independent of BMD among breast cancer patients treated with AIs. Future studies are warranted to evaluate the performance of incorporating gSOS in prediction models for the risk of AI-related fracture in breast cancer patients.
- Open Access
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
Statistically-significant findings from analysis of 2,696 White individuals
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
Statistically-significant findings from analysis of 2,696 White individuals
- Open Access
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
Dot plot of findings from analysis of 2,696 White individuals
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
Dot plot of findings from analysis of 2,696 White individuals
- Open Access
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
A dot plot summarizes the associations in the analysis of 3,902 women with breast cancer. The x-axis represents the 55 PGS for metabolic traits and the y-axis represents the seven survival outcomes. Each dot represents a PGS tertile (T3 vs. T1)-survival outcome association. The size of the point is inversely proportional to its P value. P values are from trend tests by treating T1, T2, and T3 as ordinal variables. The color of the point represents the HR. Bluer colors represent HR < 1.0, and more red colors represent HR > 1.0.
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
A dot plot summarizes the associations in the analysis of 3,902 women with breast cancer. The x-axis represents the 55 PGS for metabolic traits and the y-axis represents the seven survival outcomes. Each dot represents a PGS tertile (T3 vs. T1)-survival outcome association. The size of the point is inversely proportional to its P value. P values are from trend tests by treating T1, T2, and T3 as ordinal variables. The color of the point represents the HR. Bluer colors represent HR < 1.0, and more red colors represent HR > 1.0.
- Open Access
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
Time-varying covariates for Cox proportional hazard model
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
Time-varying covariates for Cox proportional hazard model
- Open Access
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
TABLE 2 from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
Survival events in the Pathways Study (n = 3,902)
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 2 from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
Survival events in the Pathways Study (n = 3,902)
- Open Access
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
Polygenic score models pulled from the polygenic score catalog
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
Polygenic score models pulled from the polygenic score catalog
- Open Access
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
Seven forest plots depict the HRs in the ER+ group for nominally significant (P < 0.05) survival outcome associations with PGS for seven different traits: CVD (A), coronary heart disease (B), serum albumin (C), C-reactive protein (D), SHBG (E), total serum protein (F), and hypertension (G). Each point on the plot represents a test between the PGS-tertile and breast cancer–related survival outcome. Green represents tertile 1. Violet represents tertile 2. Blue represents tertile 3. The y-axis shows the survival outcome, and the x-axis represents the HR. Horizontal lines represent 95% CIs from the Wald test. Associations with P < 0.05, but HR CIs overlapping with one were removed from the plots.
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
Seven forest plots depict the HRs in the ER+ group for nominally significant (P < 0.05) survival outcome associations with PGS for seven different traits: CVD (A), coronary heart disease (B), serum albumin (C), C-reactive protein (D), SHBG (E), total serum protein (F), and hypertension (G). Each point on the plot represents a test between the PGS-tertile and breast cancer–related survival outcome. Green represents tertile 1. Violet represents tertile 2. Blue represents tertile 3. The y-axis shows the survival outcome, and the x-axis represents the HR. Horizontal lines represent 95% CIs from the Wald test. Associations with P < 0.05, but HR CIs overlapping with one were removed from the plots.
- Open Access
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
Data from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
Previous studies suggest associations of metabolic syndromes with breast cancer prognosis, yet the evidence is mixed. In recent years, the maturation of genome-wide association study findings has led to the development of polygenic scores (PGS) for many common traits, making it feasible to use Mendelian randomization to examine associations between metabolic traits and breast cancer outcomes. In the Pathways Study of 3,902 patients and a median follow-up time of 10.5 years, we adapted a Mendelian randomization approach to calculate PGS for 55 metabolic traits and tested their associations with seven survival outcomes. Multivariable Cox proportional hazards models were used to derive HRs and 95% confidence intervals (CI) with adjustment for covariates. The highest tertile (T3) of PGS for cardiovascular disease was associated with shorter overall survival (HR = 1.34, 95% CI = 1.11–1.61) and second primary cancer–free survival (HR = 1.31, 95% CI = 1.12–1.53). PGS for hypertension (T3) was associated with shorter overall survival (HR = 1.20, 95% CI = 1.00–1.43), second primary cancer–free survival (HR = 1.24, 95% CI = 1.06–1.45), invasive disease-free survival (HR = 1.18, 95% CI = 1.01–1.38), and disease-free survival (HR = 1.21, 95% CI = 1.04–1.39). PGS for serum cystatin C levels (T3) was associated with longer disease-free survival (HR = 0.82, 95% CI = 0.71–0.95), breast event-free survival (HR = 0.74, 95% CI = 0.61–0.91), and breast cancer–specific survival (HR = 0.72, 95% CI = 0.54–0.95). The above associations were significant at a nominal P < 0.05 level but not after correcting for multiple testing (Bonferroni P < 0.0009). Our analyses revealed notable associations of PGS for cardiovascular disease, hypertension, and cystatin C levels with breast cancer survival outcomes. These findings implicate metabolic traits in breast cancer prognosis.Significance:To our knowledge, this is the largest study of PGS for metabolic traits with breast cancer prognosis. The findings revealed significant associations of PGS for cardiovascular disease, hypertension, and cystatin C levels with several breast cancer survival outcomes. These findings implicate an underappreciated role of metabolic traits in breast cancer prognosis that would warrant further exploration.
- 22 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study
Previous studies suggest associations of metabolic syndromes with breast cancer prognosis, yet the evidence is mixed. In recent years, the maturation of genome-wide association study findings has led to the development of polygenic scores (PGS) for many common traits, making it feasible to use Mendelian randomization to examine associations between metabolic traits and breast cancer outcomes. In the Pathways Study of 3,902 patients and a median follow-up time of 10.5 years, we adapted a Mendelian randomization approach to calculate PGS for 55 metabolic traits and tested their associations with seven survival outcomes. Multivariable Cox proportional hazards models were used to derive HRs and 95% confidence intervals (CI) with adjustment for covariates. The highest tertile (T3) of PGS for cardiovascular disease was associated with shorter overall survival (HR = 1.34, 95% CI = 1.11–1.61) and second primary cancer–free survival (HR = 1.31, 95% CI = 1.12–1.53). PGS for hypertension (T3) was associated with shorter overall survival (HR = 1.20, 95% CI = 1.00–1.43), second primary cancer–free survival (HR = 1.24, 95% CI = 1.06–1.45), invasive disease-free survival (HR = 1.18, 95% CI = 1.01–1.38), and disease-free survival (HR = 1.21, 95% CI = 1.04–1.39). PGS for serum cystatin C levels (T3) was associated with longer disease-free survival (HR = 0.82, 95% CI = 0.71–0.95), breast event-free survival (HR = 0.74, 95% CI = 0.61–0.91), and breast cancer–specific survival (HR = 0.72, 95% CI = 0.54–0.95). The above associations were significant at a nominal P < 0.05 level but not after correcting for multiple testing (Bonferroni P < 0.0009). Our analyses revealed notable associations of PGS for cardiovascular disease, hypertension, and cystatin C levels with breast cancer survival outcomes. These findings implicate metabolic traits in breast cancer prognosis.Significance:To our knowledge, this is the largest study of PGS for metabolic traits with breast cancer prognosis. The findings revealed significant associations of PGS for cardiovascular disease, hypertension, and cystatin C levels with several breast cancer survival outcomes. These findings implicate an underappreciated role of metabolic traits in breast cancer prognosis that would warrant further exploration.